Governance MannKind Corporation

MNKD

US56400P7069

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 13/01/2026 GMT			5-day change	1st Jan Change
5.640 ^USD	-2.25%		+0.36%	-0.53%

01-08	MannKind provides business updates and 2026 growth drivers	RE
12-23	MannKind Says FDA Approves Furoscix Autoinjector Use for Pediatric Patients With Fluid Retention	MT

Executive Committee: MannKind Corporation

Manager

Positions heldSince

Michael Castagna

49 year

Chief Executive Officer

24/05/2017

Christopher Prentiss

51 year

Comptroller/Controller/Auditor	21/04/2024
Director of Finance/CFO	21/04/2024

Sanjay Singh

59 year

Chief Tech/Sci/R&D Officer

30/09/2022

Karen Jaffe

General Counsel

31/12/2019

Kevin Kaiserman

Chief Tech/Sci/R&D Officer

30/08/2020

Stuart Tross

59 year

Human Resources Officer

30/11/2016

Joseph Kocinsky

62 year

Chief Tech/Sci/R&D Officer

30/09/2015

David Thomson

59 year

General Counsel	31/12/2001
Corporate Secretary	31/12/2001

Ajay Ahuja

Chief Tech/Sci/R&D Officer

28/09/2025

Composition of the Board of Directors: MannKind Corporation

Director

CommitteesSince

James Shannon

69 year

Compensation Committee
Governance Committee	12/06/2024
Nominating Committee	12/06/2024

Sabrina Kay

63 year

Audit Committee	30/11/2020
Compensation Committee	25/05/2022
Compensation Committee Chair
Governance Committee	25/05/2022
Nominating Committee	25/05/2022

Anthony Hooper

71 year

Audit Committee	28/02/2025
Compensation Committee Chair
Governance Committee Chair	15/01/2025
Nominating Committee Chair	15/01/2025

Michael Friedman

82 year

Compensation Committee	10/06/2009
Governance Committee	30/11/2003
Nominating Committee	30/11/2003

Christine Mundkur

57 year

Audit Committee
Governance Committee
Nominating Committee

Jennifer Grancio

54 year

Audit Committee	22/03/2020
Governance Committee Chair	22/03/2020
Nominating Committee Chair	22/03/2020

Ronald Consiglio

82 year

Governance Committee	30/09/2003
Nominating Committee	30/09/2003
Audit Committee Chair	30/09/2003

Michael Castagna

49 year

Director/Board Member

24/05/2017

Steven Binder

63 year

Director/Board Member

12/08/2024

Latest Appointments: MannKind Corporation

12-18	Cartesian Therapeutics, Inc. Announces the Appointment of Adrian Bot to Board of Directors and Member of the Science and Technology Committee	CI
29/09/25	MannKind appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer	RE
29/09/25	MannKind Corporation Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer, Effective September 29, 2025	CI
15/05/25	Mannkind Corporation Announces Burkhard Blank Step Down as Chief Medical Officer and Executive Vice President, Research & Development	CI
06/01/25	Mannkind Corporation Announces Resignation of Lauren Sabella as Executive Vice President, Operations, Effective July 18, 2025	CI
06/01/25	Dominic Marasco Joins MannKind Corporation as President, Endocrine Business Unit	CI
14/08/24	Mannkind Corporation Announces Board Changes, September 30, 2024	CI

More news

Former Officers and Directors: MannKind Corporation

Insider

Positions held

SinceUntil

Lauren Sabella

Chief Operating Officer

26/03/2023

17/07/2025

Burkhard Blank

Chief Tech/Sci/R&D Officer

23/05/2023

13/05/2025

Kent Kresa

Director/Board Member	08/12/2020	29/10/2024
Chairman	31/01/2017	08/12/2020
Independent Dir/Board Member	31/05/2004	29/10/2024

Thomas Hofmann

Chief Tech/Sci/R&D Officer

30/11/2020

31/12/2023

Alejandro Galindo

Corporate Officer/Principal

03/08/2020

31/10/2022

David M. Kendall

Chief Tech/Sci/R&D Officer

11/02/2018

27/08/2020

Courtney Barton

Compliance Officer

28/02/2017

31/10/2019

Frank Pompilio

Chief Tech/Sci/R&D Officer

31/05/2016

30/09/2019

Elizabeth Ingram

Sales & Marketing

31/05/2018

31/05/2019

Raymond Urbanski

Chief Tech/Sci/R&D Officer

09/08/2015

28/09/2017

James P. McCauley

Corporate Officer/Principal

11/07/2017

Joseph Saldanha

Sales & Marketing

19/04/2016

30/06/2017

Matthew Pfeffer

Director/Board Member	09/01/2016	24/05/2017
Chief Executive Officer	09/01/2016	24/05/2017
Director of Finance/CFO	20/04/2008	24/05/2017
Investor Relations Contact	20/04/2008	-

Robert A. Baughman

Corporate Officer/Principal

30/09/2016

Juergen A. Martens

Chief Operating Officer	08/01/2015	17/03/2016
Chief Tech/Sci/R&D Officer	31/08/2005	31/12/2014

Alfred Mann

Director/Board Member	18/02/2016	24/02/2016
Chief Executive Officer	18/11/2015	04/01/2016
Chairman	13/02/1991	18/02/2016
Founder	13/02/1991	24/02/2016

Duane DeSisto

Director/Board Member	23/12/2015	14/01/2016
Chief Executive Officer	23/12/2015	14/01/2016
President	23/12/2015	14/01/2016

Hakan S. Edstrom

Director/Board Member	30/11/2001	19/11/2015
Chief Executive Officer	08/01/2015	19/11/2015
Chief Operating Officer	31/03/2001	08/01/2015
President	31/03/2001	19/11/2015

Linda A. Adreveno

Human Resources Officer

28/02/2015

Peter Richardson

Chief Tech/Sci/R&D Officer

30/09/2005

31/12/2011

James B. Weissman

Corporate Officer/Principal

31/12/2005

31/12/2011

Janella Funes

Corporate Officer/Principal

31/12/2004

Heather Miller

Director/Board Member

30/04/2007

30/11/2008

Stephen Blackwood

Public Communications Contact	31/03/2008	31/03/2008
Treasurer	31/03/2008	31/03/2008

John R. Riesenberger

Corporate Officer/Principal

06/01/2008

Abraham E. Cohen

Director/Board Member	30/04/2007	-
Independent Dir/Board Member	30/04/2007	-

Dan R. Burns

Corporate Officer/Principal

15/02/2007

Todd Easley

Sales & Marketing

23/10/2005

John Bedard

Corporate Officer/Principal

23/10/2005

Henry Nordhoff

Director/Board Member	17/03/2005	-
Independent Dir/Board Member	17/03/2005	-

Diane M. Palumbo

Human Resources Officer

31/10/2004

David Hopper MacCallum

Director/Board Member	31/05/2004	-
Independent Dir/Board Member	31/05/2004	-

Kathleen Connell

Director/Board Member

31/10/2003

Llew Keltner

Director/Board Member

30/09/2003

Jeffrey Steven Silverman

Chief Operating Officer

31/08/2000

31/07/2003

Solomon Steiner

Director/Board Member	30/11/2001	31/01/2003
Chief Tech/Sci/R&D Officer	30/11/2001	31/01/2003

Richard L. Anderson

Director of Finance/CFO

30/09/2002

John Simard

Director/Board Member	-	31/12/2001
Corporate Officer/Principal	-	31/12/2001

Sheila A. Bergey

Corporate Officer/Principal

Wanlin Xia

Corporate Officer/Principal

Agustin Quintero

Corporate Officer/Principal

Mark T. Marino

Corporate Officer/Principal

Dina Maines

Corporate Officer/Principal

Adrian Bot

Chief Tech/Sci/R&D Officer

Cohava Gelber

Chief Tech/Sci/R&D Officer

Stephen J. McCormack

Corporate Officer/Principal

W. Wendell Cheatham

Chief Tech/Sci/R&D Officer

Carrie Liao

Comptroller/Controller/Auditor

Age distribution of managers

Parity Men Women

Male	15
Female	4

Of which Executive Committee

Male	8
Female	1

Of which Directors

Male	7
Female	2

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Employees

405

Sector

Biotechnology & Medical Research

Calendar

03-02 - Q4 2025 Earnings Release (Projected)

More about the company